» Articles » PMID: 21484798

Isolation of Disseminated Neuroblastoma Cells from Bone Marrow Aspirates for Pretreatment Risk Assessment by Array Comparative Genomic Hybridization

Overview
Journal Int J Cancer
Specialty Oncology
Date 2011 Apr 13
PMID 21484798
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

In neuroblastoma, tumor biopsies are used for prognostic evaluation and risk assessment by molecular genetic analyses such as fluorescence in situ hybridization (FISH) and array comparative genomic hybridization (array CGH). Analysis of primary tumors by array CGH can be hampered by the lack of sufficient tumor cells due to small biopsy size or availability of invaded bone marrow only. Given the importance of accurate assessment of genetic alterations in the diagnostic work-up of patients with neuroblastoma, we evaluated the possibility to analyze bone marrow metastases in patients with disseminated disease. Disseminated neuroblastoma cells were isolated from bone marrow aspirates by using either laser capture microdissection (LCM) or magnetic activated cell sorting (MACS). The array CGH profiles of these isolated metastases were compared to array CGH profiles and/or FISH data of the corresponding primary tumor. Here, we show that the major recurrent DNA copy number alterations detected in primary neuroblastoma tumors (i.e., 1p, 3p and 11q deletion, 17q gain and MYCN amplification) can be detected, with high sensitivity and specificity, in the disseminated neuroblastoma cells isolated from the bone marrow aspirates, using an array platform with high coverage for these regions. Moreover, we demonstrate that for archived material, for example, for retrospective studies, LCM is the method of choice, while for fresh bone marrow aspirates, acquired at the time of diagnosis, MACS is superior.

Citing Articles

17q Gain in Neuroblastoma: A Review of Clinical and Biological Implications.

Mlakar V, Dupanloup I, Gonzales F, Papangelopoulou D, Ansari M, Gumy-Pause F Cancers (Basel). 2024; 16(2).

PMID: 38254827 PMC: 10814316. DOI: 10.3390/cancers16020338.


Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma.

Smith J, Moreno L, Heaton S, Chesler L, Pearson A, Garrett M Mol Oncol. 2015; 10(4):538-52.

PMID: 26686971 PMC: 5423144. DOI: 10.1016/j.molonc.2015.11.005.


Deregulation of focal adhesion pathway mediated by miR-659-3p is implicated in bone marrow infiltration of stage M neuroblastoma patients.

Stigliani S, Scaruffi P, Lagazio C, Persico L, Carlini B, Varesio L Oncotarget. 2015; 6(15):13295-308.

PMID: 25980492 PMC: 4537015. DOI: 10.18632/oncotarget.3745.


Bone marrows from neuroblastoma patients: an excellent source for tumor genome analyses.

Abbasi M, Rifatbegovic F, Brunner C, Ladenstein R, Ambros I, Ambros P Mol Oncol. 2014; 9(3):545-54.

PMID: 25467309 PMC: 5528711. DOI: 10.1016/j.molonc.2014.10.010.